GlaxoSmithKline plc

Currently no vaccine is available for respiratory syncytial virus (RSV) RSV-associated lower respiratory tract illnesses (LRTIs) cause significant global morbidity

For media and investors only Issued: London UK; Philadelphia US; Geneva Switzerland GSK and Medicines for Malaria Venture (MMV) today

For media and investors only Issued: London, UK ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc

For media and investors only Issued: London, UK Dolutegravir is the first integrase inhibitor available as a dispersible tablet for

For media and investors only Issued: London, UK Data from the GLIMMER study presented as a late-breaking session at The

For media and investors only Issued: London, UK Data from the GLIMMER study presented as a late-breaking session at The

For media and investors only Issued: London, UK and Quebec City, Canada The COVID-19 vaccine candidate will contain GSK’s pandemic

For media and investors only Issued: London, UK Studies demonstrate potential of BLENREP in combination with standard therapies in earlier

For media and investors only Issued: London, UK Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every

For media and investors only Issued: London, UK Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every

For media and investors only Issued: London, UK Increasing scientific evidence[1] demonstrates that climate change and nature loss are impacting

For media and investors only Issued: London, UK Zejula is the first PARP inhibitor approved as monotherapy in the European

For media and investors only Issued: London, UK Submissions based on positive data from pivotal studies in hypereosinophilic syndrome, chronic

Emma Walmsley, Chief Executive Officer, GSK said: “GSK has responded well to a challenging operating environment this year with disciplined

For media and investors only Issued: London, UK and Paris, France COVAX Facility is led by Gavi and aims to

For media and investors only Issued: London, UK Five-year data from the LATTE-2 study and 12-month data from the rollover

For media and investors only Issued: London, UK Interim data presented at IDWeek 2020 showed the majority of patient participants

For media and investors only Issued: London, UK Phase I/II data presented at ID Week show that the two FDA

For media and investors only Issued: London, UK Positive findings presented at IDWeek™ 2020 from a pooled analysis of six

For media and investors only Issued: London, UK ViiV Healthcare’s Vocabria (cabotegravir injection) used in combination with Janssen Pharmaceutical Companies

For media and investors only Issued: London, UK The TANGO 96-week data presented at HIV Glasgow 2020 also confirm Dovato’s

For media and investors only Issued: London UK and San Francisco US Independent Data Monitoring Committee recommended on September 30,

For media and investors only Issued: London, UK ViiV Healthcare, the global specialist HIV company majority owned by GSK, with

For media and investors only Issued: London, UK Data presented will reinforce the potential to shift the treatment paradigm to

For media and investors only Issued: London, UK ViiV Healthcare, the global specialist HIV company majority owned by GSK, with